BDI-T 0.24 FIH.U-T 0 MATR-T -0.03 TOU-T -0.5 PPL-T 0.09 ZLU.U-T -0.3
Daily Stock Opinions and Ratings
Stockchase Opinions

Cameron Hurst Celgene Corp CELG-Q DON'T BUY May 09, 2018

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

Cameron HurstCameron Hurst
No
Unlock Rating
$82.800

Stock price when the opinion was issued

Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

SELL

Celgene Corp(CELG-Q)

Jan 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Christine PooleChristine Poole
No
Unlock Rating
$86.950

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Celgene Corp(CELG-Q)

Feb 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Bruce MurrayBruce Murray
Owned
Unlock Rating
$89.870

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Celgene Corp(CELG-Q)

Apr 08, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Bruce MurrayBruce Murray
Owned
Unlock Rating
$95.050

Stock price when the opinion was issued

Consumer Products
BUY

Celgene Corp(CELG-Q)

Apr 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
Gordon ReidGordon Reid
Owned
Unlock Rating
$93.420

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Celgene Corp(CELG-Q)

May 03, 2019
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Paul MacDonaldPaul MacDonald
No
Unlock Rating
$96.780

Stock price when the opinion was issued

Consumer Products
DON'T BUY

Celgene Corp(CELG-Q)

Aug 06, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

David BurrowsDavid Burrows
Unknown
Unlock Rating
$93.570

Stock price when the opinion was issued

Consumer Products
COMMENT

Celgene Corp(CELG-Q)

Sep 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

John KimJohn Kim
Unknown
Unlock Rating
$98.560

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Celgene Corp(CELG-Q)

Oct 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Ashley Misquitta, CFAAshley Misquitta, CFA
Owned
Unlock Rating
$100.970

Stock price when the opinion was issued

Consumer Products
SELL

Celgene Corp(CELG-Q)

Nov 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Gordon ReidGordon Reid
No
Unlock Rating
$108.240

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Celgene Corp(CELG-Q)

Jan 17, 2020

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$108.240

Stock price when the opinion was issued

Consumer Products

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PSD-T -0.04$3.52
V-N -7.95$347.93
BEP.UN… -0.16$34.75
BBU.UN… -0.17$35.1
ISC-T 0.3$32.8

Today's Top Picks

BDI-T 0.24$10.79
FIH.U-… 0$18.9
MATR-T -0.03$12.5
TOU-T -0.5$62.27
PPL-T 0.09$50.43

Popular Articles

Latest Sell Signals

CLS-T 3.38$220.38
TSLA-Q 3.64$313.51
ALA-T 0.17$39.2
BN-T -0.97$86.38
SLF-T 0.23$85

Most Recent Experts

Colin Stewart

Colin Stewart

JC Clark Investments Ltd.

Stockchase Insights

Stockchase Insights

5i Research

Bill Harris, CFA

Bill Harris, CFA

Avenue Investment Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica